Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIa Randomized, Double-blind, and Placebo-controlled Multicenter Split Body Trial of Repeated Doses of ACOU085 for the Prevention of Hearing Loss in Testicular Cancer Patients Receiving Cisplatin

Next Previous
X
Search
Trial Profile

Phase IIa Randomized, Double-blind, and Placebo-controlled Multicenter Split Body Trial of Repeated Doses of ACOU085 for the Prevention of Hearing Loss in Testicular Cancer Patients Receiving Cisplatin

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Sep 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ACOU 085 (Primary)
  • Indications Chemotherapy-induced damage; Sensorineural hearing loss
  • Focus Therapeutic Use
  • Acronyms PROHEAR
  • Sponsors Acousia Therapeutics

    • Most Recent Events

    • 15 Feb 2024 According to an Acousia Therapeutics media release, trial is formally endorsed by the Study Group of the German Society of Otorhinolaryngology (DSZ-HNO).
    • 15 Feb 2024 Status changed from planning to recruiting, according to an Acousia Therapeutics media release.
    • 15 Feb 2024 According to an Acousia Therapeutics media release, company announced first patient enrollment.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top